anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Biomarkers of Alzheimer's disease (AD) and mild cognitive impairment (MCI, or prodromal AD) are highly significant for early diagnosis, clinical trials and treatment outcome evaluations. Electroencephalography (EEG), being noninvasive and easily accessible, has recently been the center of focus. However, a comprehensive understanding of EEG in dementia is still needed. A primary objective of this study is to investigate which of the many EEG characteristics could effectively differentiate between individuals with AD or prodromal AD and healthy individuals.
METHODS: We collected resting state EEG data from individuals with AD, prodromal AD, and normal cognition. Two distinct preprocessing pipelines were employed to study the reliability of the extracted measures across different datasets. We extracted 41 different EEG features. We have also developed a stand-alone software application package, Feature Analyzer, as a comprehensive toolbox for EEG analysis. This tool allows users to extract 41 EEG features spanning various domains, including complexity measures, wavelet features, spectral power ratios, and entropy measures. We performed statistical tests to investigate the differences in AD or prodromal AD from age-matched cognitively normal individuals based on the extracted EEG features, power spectral density (PSD), and EEG functional connectivity.
RESULTS: Spectral power ratio measures such as theta/alpha and theta/beta power ratios showed significant differences between cognitively normal and AD individuals. Theta power was higher in AD, suggesting a slowing of oscillations in AD; however, the functional connectivity of the theta band was decreased in AD individuals. In contrast, we observed increased gamma/alpha power ratio, gamma power, and gamma functional connectivity in prodromal AD. Entropy and complexity measures after correcting for multiple electrode comparisons did not show differences in AD or prodromal AD groups. We thus catalogued AD and prodromal AD-specific EEG features.
CONCLUSIONS: Our findings reveal that the changes in power and connectivity in certain frequency bands of EEG differ in prodromal AD and AD. The spectral power, power ratios, and the functional connectivity of theta and gamma could be biomarkers for diagnosis of AD and prodromal AD, measure the treatment outcome, and possibly a target for brain stimulation.
Hypertension, a prevalent global cardiovascular disease, affects approximately 45.4 % of adults worldwide. Despite advances in therapy, hypertension continues to pose a significant health risk due to inadequate management. It has been established that excessive adiposity contributes majorly to hypertension, accounting for 65 to 75 % of primary cases. Fat depots can be categorised into subcutaneous and visceral adipose tissue based on anatomical and physiological characteristics. The metabolic impact and the risk of hypertension are determined more significantly by visceral fat. Perirenal adipose tissue (PRAT), a viscera enveloping the kidney, is known for its superior vascularisation and abundant innervation. Although traditionally deemed as a mechanical support tissue, recent studies have indicated its contributing potential to hypertension. Hypertensive patients tend to have increased PRAT thickness compared to those without, and there is a positive correlation between PRAT thickness and elevated systolic blood pressure. This review encapsulates the anatomical characteristics and biogenesis of PRAT. We provide an overview of the potential mechanisms where PRAT may modulate blood pressure, including physical compression, paracrine effects, and neurogenic regulation. PRAT has become a promising target for hypertension management, and continuous effort is required to further explore the underlying mechanisms.
Pyrogen-free, highly pure gamma-globulin is produced by intimately mixing a gamma-globulin concentrate and an unbranched, long-chain, water-soluble, uncharged polymer (mean molecular wt. e.g. 3000-20000) (pref. polyethylene glycol of molecular wt. 4000-8000) at 4-30 degrees C and pH 4-5 with an aq. fluid, separating off an insoluble fraction after phase-separation has taken place, and recovering a purified gamma-globulin fraction from the supernatant aq. phase; the amt of aqs. fluid being such that the gamma-globulin concn. in the mixed is 3-8 wt.% and the amt of polymer being such that its solubility-inhibiting in the mixt is equiv. to that of pooyethylene glycol 6000 in a concn of a 4-4, 8g/100ml. The procedure can readily be incorporated into conentional blood fractionation processes and gives highly pure gamma-globulin in good yields. The product is pyrogen-free and is free from anti-complement activity, sot hat it is suitable for i.v administration, and oes not contain traces of substances such as enzymes which would adversely affect stability.
A prompt response to glucocorticoids is a clinical hallmark of IgG4-related disease. However, manifestations characterised by prominent tissue fibrosis on histological examination can be less responsive to glucocorticoid therapy than other types of IgG4-related disease. These manifestations include retroperitoneal fibrosis, fibrosing mediastinitis, Riedel thyroiditis, orbital pseudotumor, and hypertrophic pachymeningitis, among others. To explain this discrepancy, a preliminary distinction into proliferative and fibrotic phenotypes of IgG4-related disease has been proposed on the basis of clinical presentation, pathological features, and response to immunosuppressive therapy. Implications of this classification for patient management remain an important area of investigation. In this Series paper, we aim to dissect the pathophysiology of tissue fibrosis in IgG4-related disease and discuss how clinicians should approach the management of fibrotic manifestations of IgG4-related disease based on the most recent diagnostic and therapeutic developments.
PURPOSE:The titled aqueous solution being easily dissolved in water, having low change with time, obtained by blending ubidecarenone with hydrogenated lecithin. CONSTITUTION:The titled aqueous solution comprising a blend of 1pt.wt. ubidecarenone and 0.2-15pts.wt. hydrogenated lecithin, a water-soluble solvent (e.g., propylene glycol) and/or an isotonic agent (e.g., glucose). Ubidecarenone is positioned in an electron transport system of myocardial mitochondria, plays an important role in energy production, is useful for improving hemotasis symptom such as ischemic heart disease, etc. caused by reduction in cardiac function, but it has bad absorption from the intestine and it is very difficult to dissolve ubidecarenone in water. When it is blended with hydrogenated lecithin, it is solubilized in water without using a nonionic surface active agent, and can provide an aqueous solution having a low ratio in change of transmittance and a low ratio in change of coloring degree. Hydrogenated lecithin is obtained by adding lecithin to an autoclave, bringing it into contact with hydrogen in the presence of a solvent and a catalyst, hydrogenating it until a given iodine value is reached.
The invention relates to a composite propolis composition used for treating livestock diarrhea, and a preparation method thereof. The invention relates to the field of animal medicine. The components and the preparation method of the composition provided by the invention are represented as the following: (1) all components (except interferon) in a formula are respectively subject to ultra-fine crushing, and are sieved by using a sieve of 700 meshes; (2) according to a weight ratio, 15-30 parts of propolis, 15-30 parts of java brucea fruit, 10-35 parts of officinal magnolia bark, 15-40 parts of amur corktree bark, and 10-40 parts of Baikal skullcap root are mixed for 5-10min until uniform; (3) according to a weight ratio, 10-35 parts of tuckahoe, 10-35 parts of lobed kudzuvine root, 15-45 parts of scorch-fried longleaf garden burnet root, 15-35 parts of Chinese arborvitae twig and leaf, 15-35 parts of oriental waterplantain tuber, and 15-55 parts of honeysuckle flower are mixed for 5-10min until uniform; (4) compositions obtained in the steps (2) and (3) are combined, and are mixed for 10-15min until uniform, such that the composite propolis composition is obtained. The method is advantaged in reasonable formulation and simple preparation. The composition is advantaged in no toxic or side effect, no pollution, no medicine residue, no medicine resistance, ultra-fine crushing, high bioavailability, and substantial treatment effect. As a result of clinical application, the medicine has a special effect for treating livestock diarrhea.
The invention relates to a medicine for treating hyperglycemia, and belongs to the technical field of Chinese medicines. According to the conventional method for preparing powder, the medicine for treating hyperglycemia is prepared by the following steps of: mixing 5 grams of mulberry leaf, 13 grams of wild kudzuvine root, 15 grams of spreading hedyotis herb, 15 grams of Chinese ilex fruit, 9 grams of small barberry root or stem bark, 3 grams of peach seed and 10 grams of Chinese magnoliavine fruit, crushing by using a crusher, sieving by a machine and grinding to obtain powder. According to a using method, the medicine is taken for three times every day, and 15 grams of medicine is taken every time; and hyperglycemia is treated after 5 to 20 treatment courses according to medical history, and each treatment course is 10 days. According to the medicine, Chinese medicinal herbs are purchased on markets. The medicine for treating hyperglycemia has the advantages of good curative effect, no toxic or side effect, convenience for taking and short treatment period. The medicine is taken by thousands of patients, and the cure rate is more than 95 percent.
A hybrid procoagulant factor VIII is produced by isolation and recombination of human and other nonhuman mammalian factor VIII subunits or domains, or by genetic engineering of the human and animal factor VIII genes. Subunits or domains of factor VIII that have been purified from human or animal plasma are isolated, and hybrid human/animal factor VIII is produced by (1) mixing either animal heavy chain subunits with human light chain subunits or by mixing human heavy chain subunits with animal light chain subunits, thereby producing human light chain/animal heavy chain and human heavy chain/animal light chain hybrid molecules; or by (2) mixing one or more domains of one species with one or more domains of the other species. These hybrid molecules are isolated by ion exchange chromatography. Alternatively, recombinant DNA methods are used to change elements of animal factor VIII or human factor VIII to the corresponding elements of human factor VIII or animal factor VIII, respectively, to produce hybrid human/animal factor VIII. A recombinant hybrid equivalent factor VIII molecule is produced by substituting amino acid sequence having no known factor VIII sequence identity for specific amino acid sequence in the human or animal factor VIII. The hybrid factor VIII and hybrid equivalent factor VIII molecules are administered to patients having factor VIII deficiency.
Ferroptosis is a type of regulated cell death characterized by iron-dependent lipid peroxidation. A model cell system is constructed to induce ferroptosis by re-expressing the transcription factor BACH1, a potent ferroptosis inducer, in immortalized mouse embryonic fibroblasts (iMEFs). The transfer of the culture supernatant from ferroptotic iMEFs activates the proliferation of hepatoma cells and other fibroblasts and suppresses cellular senescence-like features. The BACH1-dependent secretion of the longevity factor FGF21 is increased in ferroptotic iMEFs. The anti-senescent effects of the culture supernatant from these iMEFs are abrogated by Fgf21 knockout. BACH1 activates the transcription of Fgf21 by promoting ferroptotic stress and increases FGF21 protein expression by suppressing its autophagic degradation through transcriptional Sqstm1 and Lamp2 repression. The BACH1-induced ferroptotic FGF21 secretion suppresses obesity in high-fat diet-fed mice and the short lifespan of progeria mice. The inhibition of these aging-related phenotypes can be physiologically significant regarding ferroptosis.
PURPOSE: A composition for suppressing melanogenesis is provided to ensure excellent melanogenesis suppression. CONSTITUTION: A composition for suppressing melanogenesis contains S-(-)-10,11-dihydroxyfarnesic acid methyl ester as an active ingredient. The active ingredient is isolated from insect-derived fungi. S-dihydroxyfarnesic acid methyl ester is prepared by extracting the fungi with ethyl acetate and isolating and purifying. A pharmaceutical composition contains the composition. A cosmetic composition contains the composition. The composition is manufactured in the form of a lotion, liquid, emulsion, suspension, tablet, or capsule.
The present invention provides a method for detecting chitin-containing organisms on an area of a person of animal by contacting the particular area with a dye that is capable of binding or conjugating to chitin and emitting fluorescence upon exposure to light. If a chitin-containing organism is present in the treated area, the chitin of the organism will bind or conjugate the dye and, upon exposure to light, the chitin-containing organisms may be visualized and removed. Also provided by the present invention are solutions and suspensions that contain a dye capable of binding or conjugating to a chitin-containing organism and emitting fluorescence upon exposure to light. The solutions and suspensions provided herein may be in the form of a shampoo, cream, lotion or detergent for the detection of chitin-containing organisms present in body hair, on the skin, clothing or the fur of animals. The solutions and suspensions may also be in a form suitable for spraying on clothes, as well as on the hair, skin and fur. Further provided by the present invention are kits comprising a solution or suspension that contains a dye capable of binding or conjugating to a chitin-containing organism and a source of light that emits a wavelength capable of exciting fluorescence from the chitin-bound or chitin-conjugated dye.
Maraviroc administration will start on day -3 and will end on day +30 after stell cell transplant, making the total number of days of drug administration 34 days. Maraviroc will be administered twice daily orally or via enteral tube. Dosing of Maraviroc will be based on body surface area (starting with 100mg twice a day for BSA of 0.2 and up to 300mg twice a day for BSA greater than 1.73).
Compounds of the formula   WHEREIN R1 is CN or an alkoxycarbonyl group, R2 is NH or an oxo group, n is an integer of from 3 to 6 inclusive and the ring A may be substituted by lower alkyl or phenyl are produced by reacting a compound of the formula   WHEREIN R3 is an alkoxyl or amino group and n and ring A are as defined above with a compound of the formula   D R A W I N G WHEREIN R4 is an alkoxyl or amino group, R5 is CN or an alkoxycarbonyl group and R1 is as defined above. When R3 and R4 are both alkoxy the reaction is conducted in the presence of ammonia or an ammonia-producing substance. When R1 and R5 are both CN, R2 is NH. When one of R1 and R5 is CN and the other is an alkoxycarbonyl group, R2 is an oxo group. The compounds are useful as analgesics, antipyretics and antiinflammatories. The compounds where n is 3, 5 or 6 are novel.
A cleanser was manufd. from cucumber and hemp. Thus, cucumber was crushed, filtered, and precipitated to give hydrophilic phlegmatic temperament contg. cucurbitacin (1st process). hemp contg. saponin and collagenmucillase, balloonflower, and apricot were crushed, mixed, and fixed (2nd process). In the 2nd process, saponin was hydrolysed into sapogenin and sugar. The mixt. obtained from the 2nd process was mixed with locust bean gum to give the final product, which had 40-50≰C viscosity.
Multiple lines of evidence support the pathogenic role of neuro-inflammation in mood disorders. Our team has published a series of papers showing the inflammatory cytokines are related to severity of depressive symptoms, could be biomarkers of clinical outcomes, subtype and mood phase of bipolar disorder. Compared with depressive disorder, bipolar disorder is with more severe inflammatory dysregulation, which correlated to brain structure and functional connectivity abnormality. Treatment non-responders tended to have higher baseline inflammatory markers, suggesting that increased levels of inflammation are contributory to treatment resistance. The clinical studies showed that anti-inflammatory drugs combined with traditional treatments, can improve clinical outcomes, including N-Acetylcysteine, infliximab, pioglitazone, celecoxib, aspirin, omega-3 polyunsaturated fatty acids, minocyclin, statin, aspirin. Among them, aspirin and statin have been used for treatment and prevention of cardiovascular metabolic disorders, which are associated with inflammation dysregulation. The clinical and meta-analysis studies of aspirin and statin have shown significant efficacy and good safety. Therefore, aspirin and statin have better clinical feasibility and rationality for augmentation treatment in mood disorders. However, previous anti-inflammatory research is mostly for individual drug studies, comparative research is still quite lacking. In addition, many studies have suggested anti-inflammatory agents will likely be most useful for the subpopulation of patients whose immune dysfunction is a driving pathogenic factor.

In this study, we will establish a prediction model of anti-inflammatory drugs for mood disorder. Recent advances in deep learning have demonstrated its power to learn and recognize complex nonlinear hierarchical patterns based on largescale empirical data. A deep learning algorithm for classification applications such as medical treatment in personalized medicine is a procedure for choosing the best hypothesis from a set of alternatives that fit a set of observations. Our series of studies have shown that the severity of inflammation related with brain structure and functional connectivity abnormalities; which may be the outcome predictors. Another possible predictor may be the chromosome telomere length. Telomeres are located at the end of chromosomes and maintain normal function of chromosomes. Previous studies have found that short telomere length is associated with mood disorder, as well as the inflammatory dysregulation. Therefore, telomere length may be a predictor of anti-inflammatory treatment. The study will be the first comparative study of anti-inflammatory treatment, and establish gene-immuno-brain imaging individualized treatment prediction model. The results will provide important scientific and clinical empirical data for the inflammatory pathophysiology and treatment of mood disorders.
BACKGROUND: The aim of this study was to establish and validate a Susceptibility-weighted imaging (SWI)-based predictive model for neonatal intracranial haemorrhage (ICH).
METHODS: A total of 1190 neonates suspected of ICH after cranial ultrasound screening in a tertiary hospital were retrospectively enrolled. The neonates were randomly divided into a training cohort and a internal validation cohort by a ratio of 7:3. Univariate analysis was used to analyze the correlation between risk factors and ICH, and the prediction model of neonatal ICH was established by multivariate logistic regression based on minimum Akaike information criterion (AIC). The nomogram was externally validated in another tertiary hospital of 91 neonates. The performance of the nomogram was evaluated in terms of discrimination by the area under the curve (AUC), calibration by the calibration curve and clinical net benefit by the decision curve analysis (DCA).
RESULTS: Univariate analysis and min AIC-based multivariate logistic regression screened the following variables to establish a predictive model for neonatal ICH: Platelet count (PLT), gestational diabetes, mode of delivery, amniotic fluid contamination, 1-min Apgar score. The AUC was 0.715, 0.711, and 0.700 for the training cohort, internal validation cohort, and external validation cohort, respectively. The calibration curve showed a good correlation between the nomogram prediction and actual observation for ICH. DCA showed the nomogram was clinically useful.
CONCLUSION: We developed and validated an easy-to-use nomogram to predict ICH for neonates. This model could support individualized risk assessment and healthcare.
Flourishing is an increasingly common construct employed in the study of human wellbeing. But its appropriateness as a framework of wellbeing at certain stages of life is contested. In this paper, we consider to what extent it is possible for someone to flourish at the end of life. People with terminal illness often experience significant and protracted pain and suffering especially when they opt for treatments that prolong life. Certain aspects of human goods, however, that are plausibly constitutive of flourishing-such as meaning and purpose, deep personal relationships, and character and virtue-can be uniquely realised when life is ending. We argue that there is a qualified sense in which one can flourish at the end of life but that one must make important modifications to the criteria implicit in conventional conceptions of flourishing. We close with a discussion of the empirical assessment of wellbeing at the end of life and explore the possibility of introducing a flourishing measure in palliative care practice.
The invention discloses acute gastroenteritis pills, relates to compound pills, and in particular relates to Chinese and western medicinal compound pills for treating acute and chronic gastroenteritis. According to the technical scheme, the acute gastroenteritis pills are prepared from the following medicinal materials: 10 percent of longan seeds, 8 percent of white peony root, 15 percent of phellodendron, 15 percent of Baikal skullcap root, 10 percent of fructus aurantii, 10 percent of magnolia officinalis, 8 percent of bupleurum, 5 percent of wrinkled gianthyssop herb, 4 percent of fructus amomi, 5 percent of eupatorium, 5 percent of berberine, 3 percent of basic bismuth carbonate and 2 percent of compound camphor tincture; and the 13 gouts of medicaments are ground in a ratio and uniformly stirred to form the pills or tablets. 1.5 to 2 grams of pills are taken every time and thrice every time by using warm boiled water after dinner, and the pills are taken continuously for 2 days. Mirabilite is applied during administration. Patients suffering from gastrospasm after 2 days stop using the pills and need to immediately see a doctor. The patients should pay attention to staying warm during attack, and administrate fluid or semi-fluid.
<P>PROBLEM TO BE SOLVED: To provide an improver of swallowing difficulty, ensuring very high safety, and facilitating the administration.  <P>SOLUTION: The improver of the swallowing difficulty comprises a liquid preparation containing 0.1-0.4% (w/v) hyaluronic acid (HA) having 500,000-1,200,000 weight average molecular weight or pharmaceutically acceptable salt thereof. When it is a liquid medicine, it is used as a spray preparation or a gargling agent (including mouth wash, oral rinse, liquid dentifrice and the like). When used as the spray agent, a spray container is filled with the artificial saliva. The spray container may be a pressure-resistant spray container filled with an expandable gas in combination with the artificial saliva. A gas exhibiting acidity in a dissolved state is preferable as the expandable gas because the gas has effects for keeping the HA stably. Carbon dioxide gas is exemplified as such the gas, and is preferable.  <P>COPYRIGHT: (C)2008,JPO&INPIT